Abstract
Background
HFmrEF has been recently proposed as a distinct HF phenotype. How HFmrEF differs from HFrEF and HFpEF according to age remains poorly defined. We aimed to investigate age-dependent differences in heart failure with mid-range (HFmrEF) vs. preserved (HFpEF) and reduced (HFrEF) ejection fraction.
Methods and results
42,987 patients, 23% with HFpEF, 22% with HFmrEF and 55% with HFrEF, enrolled in the Swedish heart failure registry were studied. HFpEF prevalence strongly increased, whereas that of HFrEF strongly decreased with higher age. All cardiac comorbidities and most non-cardiac comorbidities increased with aging, regardless of the HF phenotype. Notably, HFmrEF resembled HFrEF for ischemic heart disease prevalence in all age groups, whereas regarding hypertension it was more similar to HFpEF in age ≥ 80 years, to HFrEF in age < 65 years and intermediate in age 65–80 years. All-cause mortality risk was higher in HFrEF vs. HFmrEF for all age categories, whereas HFmrEF vs. HFpEF reported similar risk in ≥ 80 years old patients and lower risk in < 65 and 65–80 years old patients. Predictors of mortality were more likely cardiac comorbidities in HFrEF but more likely non-cardiac comorbidities in HFpEF and HFmrEF with < 65 years. Differences among HF phenotypes for comorbidities were less pronounced in the other age categories.
Conclusion
HFmrEF appeared as an intermediate phenotype between HFpEF and HFrEF, but for some characteristics such as ischemic heart disease more similar to HFrEF. With aging, HFmrEF resembled more HFpEF. Prognosis was similar in HFmrEF vs. HFpEF and better than in HFrEF.
Similar content being viewed by others
Reference
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 37:2129–2200
Stein GY, Kremer A, Shochat T, Bental T, Korenfeld R, Abramson E et al (2012) The diversity of heart failure in a hospitalized population: the role of age. J Card Fail 18:645–653
Kerzner R, Gage BF, Freedland KE, Rich MW (2003) Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction. Am Heart J 146:286–290
Paren P, Schaufelberger M, Bjorck L, Lappas G, Fu M, Rosengren A (2014) Trends in prevalence from 1990 to 2007 of patients hospitalized with heart failure in Sweden. Eur J Heart Fail 16:737–742
Conde-Martel A, Formiga F, Perez-Bocanegra C, Armengou-Arxe A, Muela-Molinero A, Sanchez-Sanchez C et al (2013) Clinical characteristics and 1-year survival in heart failure patients more than 85 years of age compared with younger. Eur J Intern Med 24:339–345
Koifman E, Kopel E, Medvedovsky D, Maor E, Hamdan A, Goldenberg I et al (2013) Age-dependent effect of left ventricular ejection fraction on long-term mortality in patients with heart failure (from the Heart Failure Survey in ISrael). Am J Cardiol 112:1901–1906
Mahjoub H, Rusinaru D, Souliere V, Durier C, Peltier M, Tribouilloy C (2008) Long-term survival in patients older than 80 years hospitalised for heart failure. A 5-year prospective study. Eur J Heart Fail 10:78–84
Holmstrom A, Sigurjonsdottir R, Edner M, Jonsson A, Dahlstrom U, Fu ML (2013) Increased comorbidities in heart failure patients ≥ 85 years but declined from > 90 years: data from the Swedish Heart Failure Registry. Int J Cardiol 167:2747–2752
Tschope C, Birner C, Bohm M, Bruder O, Frantz S, Luchner A et al (2018) Heart failure with preserved ejection fraction: current management and future strategies: expert opinion on the behalf of the nucleus of the “Heart Failure Working Group” of the German Society of Cardiology (DKG). Clin Res Cardiol 107:1–19
Jonsson A, Edner M, Alehagen U, Dahlstrom U (2010) Heart failure registry: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail 12:25–31
Lam CS, Solomon SD (2014) The middle child in heart failure: heart failure with mid-range ejection fraction (40–50%). Eur J Heart Fail 16:1049–1055
Kapoor JR, Kapoor R, Ju C, Heidenreich PA, Eapen ZJ, Hernandez AF et al (2016) Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. JACC Heart Fail 4:464–472
Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ et al (2014) Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J 168:721–730
MacDonald MR, Wee PP, Cao Y, Yang DM, Lee S, Tong KL et al (2016) Comparison of characteristics and outcomes of heart failure patients with preserved versus reduced ejection fraction in a multiethnic southeast Asian cohort. Am J Cardiol 118:1233–1238
Salamanca-Bautista P, Conde-Martel A, Aramburu-Bodas O, Formiga F, Trullas JC, Quesada-Simon MA et al (2016) Precipitating factors of heart failure admission: differences related to age and left ventricular ejection fraction. Int J Cardiol 219:150–155
Ho JE, Enserro D, Brouwers FP, Kizer JR, Shah SJ, Psaty BM et al (2016) Predicting heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes. Circ Heart Fail 9:1941–3289
Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH et al (2007) Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol 50:768–777
Bauer A, Khalil M, Ludemann M, Bauer J, Esmaeili A, De-Rosa R et al (2018) Creation of a restrictive atrial communication in heart failure with preserved and mid-range ejection fraction: effective palliation of left atrial hypertension and pulmonary congestion. Clin Res Cardiol 107:845–857
Farmakis D, Simitsis P, Bistola V, Triposkiadis F, Ikonomidis I, Katsanos S et al (2017) Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. Clin Res Cardiol 106:359–368
Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A et al (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355:260–269
Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251–259
Tribouilloy C, Rusinaru D, Mahjoub H, Souliere V, Levy F, Peltier M et al (2008) Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 29:339–347
Cohn JN, Johnson G (1990) Heart failure with normal ejection fraction. The V-HeFT study. Veterans administration cooperative study group. Circulation 81:48–53
Ghali JK, Kadakia S, Bhatt A, Cooper R, Liao Y (1992) Survival of heart failure patients with preserved versus impaired systolic function: the prognostic implication of blood pressure. Am Heart J 123:993–997
Kontogeorgos S, Thunstrom E, Johansson MC, Fu M (2017) Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study. Int J Cardiol 232:86–92
Funding
This study is supported by the Swedish Heart–Lung Foundation, the Swedish agreement between the government and the county councils concerning economic support for providing an infrastructure for research and education of doctors (ALF) and the Regional Development Fund, Västra Götaland County, Sweden (FOU-VGR).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Xiaojing Chen: none. Gianluigi Savarese: none relevant for the present work. Unrelated to the present work: Research funding from the Italian Society of Cardiology on behalf of MSD Italia-Merck Sharp & Dohme Corporation; travel grants from Heart and Lung Foundation. Ulf Dahlström: none. Lars H. Lund: research grants to author’s institution: AstraZeneca, Novartis, Boston Scientiifc; speaker’s honoraria: AstraZeneca, Novartis, StJude, Merck; consulting honoraria: AstraZeneca, Novartis, Sanofi, Bayer, Vifor Pharma, Relypsa, Merck, HeartWare. Micheal Fu: none relevant for the present work. Unrelated to the present work: research funding and/or honoraria from AstraZeneca, Novartis, TRIOMED, and SERVIER.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Chen, X., Savarese, G., Dahlström, U. et al. Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction. Clin Res Cardiol 108, 1394–1405 (2019). https://doi.org/10.1007/s00392-019-01477-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-019-01477-z